Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)

NCT01683422 is registered in ClinicalTrials.gov with Loma Linda University as lead sponsor.

NCT NCT01683422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)
Lead sponsor
Loma Linda University
Phase
Not applicable
Overall status
Terminated
Start date
January 2, 2013
Completion date
February 19, 2019
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer